|Catalog Number||Pack Size||List Price*||Quantity|
* CHF, excl. 7.7% VAT and shipping costs
You are currently not logged in.
Please register to see prices including your discount. Registration may take up to 24h. For guest orders the standard discount of your institution will apply and discounts are visible on the order confirmation.
35% discount on MedChem product orders above CHF 1'000 !
- 1st November - 31st December 2023
- Not cumulative with the "30% off Screening Libraries Promotion"
Monalizumab is a first-in-class immune checkpoint inhibitor targeting Natural Killer Group 2A (NKG2A). Monalizumab, a humanized anti-NKG2A blocking mAb, increases IFN-γ production, thereby promoting NK cell effector functions. Monalizumab can be used for the research of head and neck squamous cell carcinoma (HNSCC).
|Research Field||Cancer, Inflammation/Immunology, Cell Cycle/DNA Damage,Immunology/Inflammation|
|Grade||Clinical information: Phase 3|
|Storage Conditions||Store at -80°C for 2 years|
|Disclaimer||Shipped on dry ice - extra freight charge will occur|
|Tech. Data Sheet||View datasheet|
|Link To Supplier||http://www.medchemexpress.com|
|Shipping Details||Dry Ice|
|Material Safety Data Sheet||Download PDF|